Resources

  1. Stene-Johansen K, Yaqoob N, Øverbø J, Aberra H, Desalegn H, Berhe N, Johannessen A.Dried blood spots a reliable method for measurement of HBV viral load in resource-limited settings. PLoS ONE 2016; 11(11): e0166201.
  2. Desalegn H, Aberra H, Berhe N, Gundersen SG, Johannessen A. Are non-invasive fibrosis markers for chronic hepatitis B valid in sub-Saharan Africa? Liver Int 2017;37(10):1461-7
  3. Desalegn H, Johannessen A. Response to Non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa. Liver Int 2017;37(11):1739.
  4. Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG, Johannessen A. Early experiences from one of the largest treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis 2017;17(1):438
  5. Aberra H, Gordien E, Desalegn H, Berhe N, Medhin G, Mekasha B, Gundersen SG, Gerber A, Stene-Johansen K, Øverbø J, Johannessen A. Hepatitis delta infection in a large cohort of chronic hepatitis B patients in Ehiopia. Liver Int 2018;38(6):1000-1009.
  6. Orlien SMS, Ismael NY, Ahmed TA, Berhe NB, Lauritzen T, Roald B, Goldin RD, Stene-Johansen K, Dyrhol-Riise AM, Gundersen SG, Morgan MY, Johannessen A. Unexplained chronic liver disease in Ethiopia: a cross-sectional study. BMC Gastroenterol 2018;18:27.
  7. Orlien SMS, Sandven I, Morgan MY, Berhe NB, Ismael NY, Ahmed TA, Stene-Johansen K, Gundersen SG, Johannessen A. Khat chewing increases the risk for developing chronic liver disease: a hospital-based case-control study. Hepatology 2018;68(1):248-257.
  8. Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, Pereira AP, Gundersen SG, Johannessen A. Treatment of chronic hepatitis B in sub-Saharan Africa: one-year results of a pilot treatment program. BMC Medicine 2018;16:234.
  9. Orlien SMS, Ahmed TA, Ismael NY, Berhe NB, Lauritzen T, Gundersen SG, Johannessen A. High seroprevalence of autoantibodies typical of autoimmune liver disease in eastern Ethiopia: is chewing of khat (Catha edulis) a triggering factor? Can J Gastroenterol Hepatol 2018:4980597.
  10. Aberra H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, Johannessen A. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J Hepatol 2019;70:1065-71.
  11. Orlien SMS, Berhe NB, Morgan MY, Johannessen A. Khat-related liver disease in sub-Saharan Africa: neglected, yet important. Lancet Glob Health 2019;7(3):e310.
  12. Desalegn H, Aberra H, Berhe N, Medhin G, Mekasha B, Gundersen SG, Johannessen A. Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study. BMC Gastroenterology 2019;19:74.
  13. Johannessen A, Aberra H, Desalegn H, Gordien E, Berhe N. A novel score to select patients for treatment in chronic hepatitis B: results from a large Ethiopian cohort. J Hepatol 2019;71:840-41.
  14. Desalegn H, Chanie Y, Shume P, Delil M, Gupta N, Johannessen A. Assessment of non-invasive fibrosis markers in patients with chronic hepatitis C in Ethiopia. Clin Liver Dis 2020;16:168-172.
  15. Woldemedihn GM, Rueegg CS, Desalegn H, Aberra H, Berhe N, Johannessen A. Validity of a point-of-care viral load test for hepatitis B in a low-income setting. J Virol Methods 2021;289:114057.
  16. Johannessen A, Mekasha B, Desalegn H, Aberra H, Stene-Johansen K, Berhe N. Mother-to-child transmission of hepatitis B virus in Ethiopia. Vaccines 2021;9:430.
  17. Orlien SMS, Ahmed TA, Ismael NY, Berhe NB, Bakken-Kran AM, Gundersen SG, Johannessen A. Field performance of HBsAg rapid diagnostic tests in rural Ethiopia. J Virol Methods 2021;289:114061.
  18. Johannessen A, Gebremedhin LT, Desalegn H. New WHO hepatitis B treatment guidelines: look to Ethiopia. Lancet Global Health 2022;10:e1711-e1712.
  19. Johannessen A. Is it time for a paradigm shift in treatment guidelines for chronic hepatitis B? Lancet Gastroenterol Hepatol 2023;8:784.
  20. Woldemedihn GM, Aberra H, Desalegn H, Berhe N, Rueegg CS, Johannessen A. The effect of long-term tenofovir disoproxil fumarate (TDF) treatment on renal outcomes in patients with chronic hepatitis B. Open Forum Infect Dis 2023;10:ofad404.
  21. Desalegn H, Orlien SMS, Aberra H, Mamo E, Grude S, Hommersand K, Berhe N, Gundersen SG, Johannessen A. Five-year results of a treatment program for chronic hepatitis B in Ethiopia. BMC Medicine 2023;21:373.